News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) Prices Public Offering of Common Stock


1/16/2013 9:18:39 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 8,000,000 shares of its common stock at a public offering price of $20.13 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 22, 2013, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers and representatives of the underwriters for the offering. Deutsche Bank Securities Inc., Piper Jaffray & Co., Leerink Swann LLC, Needham & Company, LLC and JMP Securities LLC are acting as co-managers for the offering. Alnylam has granted the underwriters a 30-day option to purchase up to 1,200,000 shares to cover overallotments, if any.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES